For refractory acute myeloid leukemia (AML), agents that promote β- catenin degradation; for basal cell carcinoma, hedgehog inhibitors; and for SHH-subtype medulloblastoma and newly diagnosed AML, SMO inhibitors have been tried [75]. This evidence concerns the gene SMO and acute myeloid leukemia.